tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tarsus Pharmaceuticals reports Q2 EPS (48c), consensus (36c)

Reports Q2 revenue $102.66M, consensus $95.81M. “As we approach the two-year anniversary of the XDEMVY launch, we have delivered our strongest quarter to date with over $100 million in net sales and established XDEMVY as the standard of care for Demodex blepharitis,” said Bobak Azamian, Chief Executive Officer and Chairman of Tarsus. “We now believe its peak potential is even greater than we initially expected at launch. With strong ongoing commercial execution, a differentiated pipeline, and a focus on category creation, we remain confident in our ability to drive sustained growth and position ourselves for long-term leadership in eye care.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1